Literature DB >> 20190807

Retinoid-suppressed phosphorylation of RARalpha mediates the differentiation pathway of osteosarcoma cells.

P Luo1, X Yang, M Ying, P Chaudhry, A Wang, H Shimada, W A May, G B Adams, D Mock, T J Triche, Q He, L Wu.   

Abstract

Although retinoic acid (RA) is a potent agent that coordinates inhibition of proliferation with differentiation of many cell types, RA-mediated signaling pathways in osteosarcoma cell differentiation are uncharacterized. In this study, we show that in human U2OS osteosarcoma cells, decreased phosphorylation of RA receptor alpha (RARalpha) by RA treatment or overexpressing a phosphorylation-defective mutant RARalphaS77A results in the inhibition of proliferation and induction of differentiation, and that U2OS cells transduced with RARalphaS77A suppresses tumor formation in nude mice. Moreover, using different human primary osteosarcoma cells and human mesenchymal stem cells for gene expression analysis, we found that either RA or RARalphaS77A induces many of the same differentiation response pathways and signaling molecules involved in U2OS cell differentiation. In addition, overexpression of the fibroblast growth factor 8f (FGF8f), one of the downstream targets induced by both RA and RARalphaS77A in U2OS cells, inhibits proliferation and induces expression of osteoblastic differentiation regulators. Hence, these data strongly suggest that RA-suppressed phosphorylation of RARalpha induces FGF8f expression to mediate differentiation response pathway in U2OS osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190807     DOI: 10.1038/onc.2010.50

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα.

Authors:  Lei Zhang; Qian Zhou; Ning Zhang; Weixu Li; Meidan Ying; Wanjing Ding; Bo Yang; Qiaojun He
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

2.  Retinoid-regulated FGF8f secretion by osteoblasts bypasses retinoid stimuli to mediate granulocytic differentiation of myeloid leukemia cells.

Authors:  Parvesh Chaudhry; Xiaochun Yang; Michael Wagner; Ambrose Jong; Lingtao Wu
Journal:  Mol Cancer Ther       Date:  2011-12-01       Impact factor: 6.261

Review 3.  Role of osteopontin in osteosarcoma.

Authors:  Yu-Sheng Li; Zhen-Han Deng; Chao Zeng; Guang-Hua Lei
Journal:  Med Oncol       Date:  2014-12-17       Impact factor: 3.064

4.  The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα.

Authors:  M Ying; L Zhang; Q Zhou; X Shao; J Cao; N Zhang; W Li; H Zhu; B Yang; Q He
Journal:  Oncogene       Date:  2016-01-18       Impact factor: 9.867

Review 5.  Solid tumor differentiation therapy - is it possible?

Authors:  Filemon Dela Cruz; Igor Matushansky
Journal:  Oncotarget       Date:  2012-05

6.  Gene expression profiling analysis of osteosarcoma cell lines.

Authors:  Lu Sun; Jie Li; Bing Yan
Journal:  Mol Med Rep       Date:  2015-06-18       Impact factor: 2.952

7.  Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells.

Authors:  Ning Zhang; Mei-Dan Ying; Yong-Ping Wu; Zhi-Hong Zhou; Zhao-Ming Ye; Hang Li; Ding-Sheng Lin
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

8.  CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Authors:  Marika Sciandra; Maria Teresa Marino; Maria Cristina Manara; Clara Guerzoni; Maria Grano; Angela Oranger; Enrico Lucarelli; Pier-Luigi Lollini; Barbara Dozza; Loredana Pratelli; Maria Flavia Di Renzo; Mario Paolo Colombo; Piero Picci; Katia Scotlandi
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

9.  Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy.

Authors:  Ean-Jeong Seo; Thomas Efferth
Journal:  Oncotarget       Date:  2016-03-29

10.  Human osteosarcoma CD49f(-)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity.

Authors:  M Ying; G Liu; H Shimada; W Ding; W A May; Q He; G B Adams; L Wu
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.